Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 3/20 | 0.53 |
| ▸ | RAMP1 | O60894 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.51 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | F2 | P00734 | 1/20 | 0.51 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.50 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.50 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thymoctonan SCHEMBL1230532 | 0.90 | REN (0.52) | CALCRLRAMP1OPRD1KEAP1F2 | |
| Thymoctonan SCHEMBL15532000 | 0.90 | REN (0.52) | CALCRLRAMP1OPRD1KEAP1F2 | |
| SCHEMBL29546599 | 0.90 | CALCRL (0.53) | CALCRLRAMP1KEAP1 | |
| SCHEMBL29579500 | 0.89 | CALCRL (0.59) | CALCRLRAMP1OPRD1F2NTSR2 | |
| SCHEMBL29471358 | 0.88 | CALCRL (0.54) | CALCRLRAMP1KEAP1 | |
| SCHEMBL29580071 | 0.88 | CALCRL (0.61) | CALCRLRAMP1OPRD1 | |
| SCHEMBL30259604 | 0.87 | REN (0.53) | CALCRLRAMP1OPRD1F2NTSR2 | |
| SCHEMBL30088927 | 0.87 | BACE1 (0.55) | CALCRLRAMP1 | |
| SCHEMBL30923399 | 0.87 | SLC6A2 (0.58) | CALCRLOPRD1F2NTSR2NTSR1 | |
| SCHEMBL29579417 | 0.86 | CALCRL (0.62) | CALCRLRAMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250214981-A1 | COMPOUND AND APPLICATION THEREOF IN PREPARATION OF MEDICINE FOR TREATING ENTEROVIRUS-RELATED DISEASES | SHANGHAITECH UNIVERSITY (CN) | 2025-07-03 | — | — | US | disclosed |
| EP-4509503-A1 | COMPOUND AND APPLICATION THEREOF IN PREPARATION OF MEDICINE FOR TREATING ENTEROVIRUS-RELATED DISEASES | ShanghaiTech University (CN) | 2025-02-19 | — | — | EP | disclosed |
| CN-118922415-A | Compound and application thereof in preparation of medicines for treating enterovirus-related diseases | 上海科技大学 | 2024-11-08 | — | — | CN | disclosed |
| WO-2023198067-A1 | COMPOUND AND APPLICATION THEREOF IN PREPARATION OF MEDICINE FOR TREATING ENTEROVIRUS-RELATED DISEASES | 上海科技大学 | 2023-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250214981-A1 | COMPOUND AND APPLICATION THEREOF IN PREPARATION OF MEDICINE FOR TREATING ENTEROVIRUS-RELATED DISEASES | TMPRSS15, VIP, GTF3C4 | CALCRL 2704/4885RAMP1 1849/4885OPRD1 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.